Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast.
Chemotherapy
Lobular breast cancer
Neoadjuvant
Survival
Triple negative
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
06
03
2023
accepted:
21
04
2023
medline:
7
6
2023
pubmed:
21
5
2023
entrez:
20
5
2023
Statut:
ppublish
Résumé
Triple-negative invasive lobular carcinoma (TN-ILC) of breast cancer is a rare disease and the clinical outcomes and prognostic factors are not well-defined. Women with stage I-III TN-ILC or triple-negative invasive ductal carcinoma (TN-IDC) of the breast undergoing mastectomy or breast-conserving surgery between 2010 and 2018 in the National Cancer Database were included. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare overall survival (OS) and evaluate prognostic factors. Multivariate logistic regression was performed to analyze the factors associated with pathological response to neoadjuvant chemotherapy. The median age at diagnosis for women with TN-ILC was 67 years compared to 58 years in TN-IDC (p < 0.001). There was no significant difference in the OS between TN-ILC and TN-IDC in multivariate analysis (HR 0.96, p = 0.44). Black race and higher TNM stage were associated with worse OS, whereas receipt of chemotherapy or radiation was associated with better OS in TN-ILC. Among women with TN-ILC receiving neoadjuvant chemotherapy, the 5-year OS was 77.3% in women with a complete pathological response (pCR) compared to 39.8% in women without any response. The odds of achieving pCR following neoadjuvant chemotherapy were significantly lower in women with TN-ILC compared to TN-IDC (OR 0.53, p < 0.001). Women with TN-ILC are older at diagnosis but have similar OS compared to TN-IDC after adjusting for tumor and demographic characteristics. Administration of chemotherapy was associated with improved OS in TN-ILC, but women with TN-ILC were less likely to achieve complete response to neoadjuvant therapy compared to TN-IDC.
Identifiants
pubmed: 37210429
doi: 10.1007/s10549-023-06959-3
pii: 10.1007/s10549-023-06959-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217-224Subventions
Organisme : NCI NIH HHS
ID : K12 CA090628
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju055
doi: 10.1093/jnci/dju055
pubmed: 24777111
pmcid: 4580552
DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. CA: A Cancer J for Clin 69(6):438–51
Bonotto M, Gerratana L, Poletto E et al (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19(6):608–615
doi: 10.1634/theoncologist.2014-0002
pubmed: 24794159
pmcid: 4041678
Kohler BA, Sherman RL, Howlader N et al (2015) Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):048
doi: 10.1093/jnci/djv048
Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767
doi: 10.1172/JCI45014
pubmed: 21633166
pmcid: 3127435
Luveta J, Parks RM, Heery DM, Cheung KL, Johnston SJ (2020) Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. Oncol Ther 8(1):1–11
doi: 10.1007/s40487-019-00105-0
pubmed: 32700069
Li CI, Anderson BO, Daling JR, Moe RE (2003) Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289(11):1421–1424
doi: 10.1001/jama.289.11.1421
pubmed: 12636465
Ferlicot S, Vincent-Salomon A, Médioni J et al (2004) Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 40(3):336–341
doi: 10.1016/j.ejca.2003.08.007
pubmed: 14746850
Reed AE, Kutasovic JR, Lakhani SR, Simpson PT (2015) Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics. Breast Cancer Res BCR. https://doi.org/10.1186/s13058-015-0519-x
doi: 10.1186/s13058-015-0519-x
pubmed: 25897948
Rakha EA, Gill MS, El-Sayed ME et al (2009) The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. Breast Cancer Res Treat 114(2):243–250
doi: 10.1007/s10549-008-0007-4
pubmed: 18404368
Montagna E, Maisonneuve P, Rotmensz N et al (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13(1):31–39
doi: 10.1016/j.clbc.2012.09.002
pubmed: 23098574
Bergeron A, MacGrogan G, Bertaut A et al (2021) Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol 34(7):1282–1296
doi: 10.1038/s41379-021-00742-9
pubmed: 33753865
pmcid: 8216909
Katz A, Saad ED, Porter P, Pusztai L (2007) Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 8(1):55–62
doi: 10.1016/S1470-2045(06)71011-7
pubmed: 17196511
Katz A (2005) Does neoadjuvant/adjuvant chemotherapy change the natural history of classic invasive lobular carcinoma? J Clin Oncol 23(27):6796
doi: 10.1200/JCO.2005.02.1402
pubmed: 16170189
Valero V, Buzdar AU, McNeese M, Singletary E, Hortobagyi GN (2002) Primary chemotherapy in the treatment of breast cancer: the university of Texas M. D. anderson cancer center experience. Clin Breast Cancer 3:S63–S68
doi: 10.3816/CBC.2002.s.014
pubmed: 12435294
Loibl S, Volz C, Mau C et al (2014) Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 144(1):153–162
doi: 10.1007/s10549-014-2861-6
pubmed: 24504379
O’Connor DJ, Davey MG, Barkley LR, Kerin MJ (2022) Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis. Breast 61:1–10
doi: 10.1016/j.breast.2021.11.017
pubmed: 34864494
About the National Cancer Database | ACS [Internet]. [Cited 2022 Jun 15]. Available from: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/about/
https://www.naaccr.org/wp-content/uploads/2021/01/SSDI-Manual_v-2.0.pdf .
Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG (2018) The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer 9(2):296–303
doi: 10.7150/jca.22280
pubmed: 29344276
pmcid: 5771337
Yang C, Lei C, Zhang Y et al (2020) Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: a propensity score matching study based on SEER database. Front Oncol 22(10):2844
Johnson K, Sarma D, Hwang ES (2015) Lobular breast cancer series: imaging. Breast Cancer Res 17(1):1–8
doi: 10.1186/s13058-015-0605-0
Krecke KN, Gisvold JJ (1993) Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 161(5):957–960
doi: 10.2214/ajr.161.5.8273634
pubmed: 8273634
Rakha EA, Ellis IO (2010) Lobular breast carcinoma and its variants. Semin Diagn Pathol 27(1):49–61
doi: 10.1053/j.semdp.2009.12.009
pubmed: 20306830
Yadav S, Couch FJ (2019) Germline genetic testing for breast cancer risk: the past, present, and future. Am Soc Clin Oncol Educ Book 39:61–74
doi: 10.1200/EDBK_238987
pubmed: 31099663
Yadav S, Hu C, Nathanson KL et al (2021) Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast. J Clin Oncol 39(35):3918–3926
doi: 10.1200/JCO.21.00640
pubmed: 34672684
pmcid: 8660003
Conforti F, Pala L, Pagan E et al (2021) Biological and clinical features of triple negative invasive lobular carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast 59:94–101
doi: 10.1016/j.breast.2021.06.011
pubmed: 34217971
pmcid: 8261657
Leon-Ferre RA, Hieken TJ, Boughey JC (2021) the landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol 28(4):2111–2119
doi: 10.1245/s10434-020-09480-9
pubmed: 33486641
pmcid: 8818316
National Comprehensive Cancer Network. Breast Cancer (Version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . 2022. Accessed on 10 March 2022
An X, Lei X, Huang R et al (2020) Adjuvant chemotherapy for small, lymph node–negative, triple-negative breast cancer: a single-center study and a meta-analysis of the published literature. Cancer 126(S16):3837–3846
doi: 10.1002/cncr.32878
pubmed: 32710666
Steward LT, Gao F, Taylor MA, Margenthaler JA (2014) Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncol Lett 7(2):548–552
doi: 10.3892/ol.2013.1700
pubmed: 24396485
Wang J, Shi M, Ling R et al (2011) Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial. Radiother Oncol 100(2):200–204
doi: 10.1016/j.radonc.2011.07.007
pubmed: 21852010
Tao L, Gomez SL, Keegan THM, Kurian AW, Clarke CA (2015) Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev 24(7):1039
doi: 10.1158/1055-9965.EPI-15-0243
pubmed: 25969506
pmcid: 4490947
Sullivan HC, Oprea-Ilies G, Adams AL et al (2014) Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. Appl Immunohistochem Mol Morphol 22(1):17–23
doi: 10.1097/PAI.0b013e318281148e
pubmed: 23455177
Symmans WF, Wei C, Gould R et al (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35(10):1049–1060
doi: 10.1200/JCO.2015.63.1010
pubmed: 28135148
pmcid: 5455352
Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147–2159
doi: 10.1056/NEJMoa1612645
pubmed: 28564564
Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821
doi: 10.1056/NEJMoa1910549
pubmed: 32101663
Tutt ANJ, Garber JE, Kaufman B et al (2021) Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med 384(25):2394–2405
doi: 10.1056/NEJMoa2105215
pubmed: 34081848
pmcid: 9126186
Riba LA, Russell T, Alapati A, Davis RB, James TA (2019) Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma. J Surg Res 233:436–443
doi: 10.1016/j.jss.2018.08.011
pubmed: 30502283
Tille JC, Vieira AF, Saint-Martin C et al (2020) Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Mod Pathol 33(11):2198–2207
doi: 10.1038/s41379-020-0561-9
pubmed: 32404955